Влияние генно-инженерной биологической терапии на течение ювенильного артрита с системным началом у детей

Аннотация

The article demonstrates the effect of genetically engineered biological therapy on the clinical course of systemic onset juvenile arthritis in children. The analysis of the results showed that the administration of human monoclonal antibodies against the IL-6 receptor - a geneticallyengineered biological drug (tocilizumab) was confirmed by normalization of clinical symptoms and laboratory parameters, reduced disease activity, prevented oral administration of glucocorticoids and systemic initiating juvenile arthritis. provided the transition to the stage. The results obtained showed that the addition of tocilizumab to the complex treatment of systemic onset juvenile arthritis was correct, and confirmed its high efficacy in the treatment of this orphan disease in children.